Cargando…

Ibrexafungerp, a Novel Triterpenoid Antifungal in Development for the Treatment of Mold Infections

Molds are ubiquitous in the environment, and immunocompromised patients are at substantial risk of morbidity and mortality due to their underlying disease and the resistance of pathogenic molds to currently recommended antifungal therapies. This combination of weakened-host defense, with limited ant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Angulo, David A., Alexander, Barbara, Rautemaa-Richardson, Riina, Alastruey-Izquierdo, Ana, Hoenigl, Martin, Ibrahim, Ashraf S., Ghannoum, Mahmoud A., King, Thomas R., Azie, Nkechi E., Walsh, Thomas J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9695964/ https://www.ncbi.nlm.nih.gov/pubmed/36354888 http://dx.doi.org/10.3390/jof8111121

Ejemplares similares

Ibrexafungerp: A Novel Oral Triterpenoid Antifungal in Development for the Treatment of Candida auris Infections
por: Ghannoum, Mahmoud, et al.
Publicado: (2020)

Ibrexafungerp, a Novel Oral Triterpenoid Antifungal in Development: Overview of Antifungal Activity Against Candida glabrata
por: Gamal, Ahmed, et al.
Publicado: (2021)

P056 Oral Ibrexafungerp outcomes by fungal disease in patients from an interim analysis of a Phase 3 Open-label Study (FURI)
por: Prattes, Juergen, et al.
Publicado: (2022)

1251. Prevention of Pneumocystis Pneumonia by Ibrexafungerp in a Murine Prophylaxis Model
por: Borroto-Esoda, Katyna, et al.
Publicado: (2020)

871. Oral Ibrexafungerp Outcomes by Fungal Disease in Patients from an Interim Analysis of a Phase 3 Open-label Study (FURI)
por: Thompson, George R, et al.
Publicado: (2022)

123. Oral Ibrexafungerp Outcomes by Fungal Disease in Patients from an Interim Analysis of a Phase 3 Open-label Study (FURI)
por: Pappas, Peter G, et al.
Publicado: (2021)

733. Ibrexafungerp Demonstrates Potent and Consistent In Vitro Activity Against >400 Global Candida auris Isolates, Including isolates with Elevated MIC’s to Echinocandins
por: Borroto-Esoda, Katyna, et al.
Publicado: (2020)

Phase 2 Randomized Study of Oral Ibrexafungerp Versus Fluconazole in Vulvovaginal Candidiasis
por: Nyirjesy, Paul, et al.
Publicado: (2021)

In Vitro pH Activity of Ibrexafungerp against Fluconazole-Susceptible and -Resistant Candida Isolates from Women with Vulvovaginal Candidiasis
por: Sobel, Jack D., et al.
Publicado: (2021)

Oral Ibrexafungerp for Vulvovaginal Candidiasis Treatment: An Analysis of VANISH 303 and VANISH 306
por: Goje, Oluwatosin, et al.
Publicado: (2023)

1248. Efficacy and Safety of Oral Ibrexafungerp in 41 Patients with Refractory Fungal Diseases, Interim Analysis of a Phase 3 Open-label Study (FURI)
por: Alexander, Barbara D, et al.
Publicado: (2020)

The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
por: Hoenigl, Martin, et al.
Publicado: (2021)

Ibrexafungerp Versus Placebo for Vulvovaginal Candidiasis Treatment: A Phase 3, Randomized, Controlled Superiority Trial (VANISH 303)
por: Schwebke, Jane R, et al.
Publicado: (2021)

Efficacy and safety of oral ibrexafungerp for the treatment of acute vulvovaginal candidiasis: a global phase 3, randomised, placebo‐controlled superiority study (VANISH 306)
por: Sobel, R, et al.
Publicado: (2021)

Ibrexafungerp: A First-in-Class Oral Triterpenoid Glucan Synthase Inhibitor
por: Jallow, Sabelle, et al.
Publicado: (2021)

672. Activity of Ibrexafungerp (Formerly SCY-078) Against Candida auris: In vitro, In Vivo, and Clinical Case Studies of Candidemia
por: Barat, Stephen, et al.
Publicado: (2019)

P057 All- cause mortality in patients with invasive Candidiasis or candidemia from an interim analysis of a Phase 3 Open-label Study (FURI)
por: Prattes, Juergen, et al.
Publicado: (2022)

466. All-Cause Mortality in Patients with Invasive Candidiasis or Candidemia from an Interim Analysis of a Phase 3 Open-label Study (FURI)
por: Prattes, Juergen, et al.
Publicado: (2022)

Pharmacokinetics and Pharmacodynamics of Ibrexafungerp
por: McCarthy, Matthew William
Publicado: (2021)

In Vitro Activity of Ibrexafungerp against a Collection of Clinical Isolates of Aspergillus, Including Cryptic Species and Cyp51A Mutants, Using EUCAST and CLSI Methodologies
por: Rivero-Menendez, Olga, et al.
Publicado: (2021)

Treatment of Recurrent Vulvovaginal Candidiasis With Ibrexafungerp
por: Grant, Leah M., et al.
Publicado: (2022)

Detecting Azole-Antifungal Resistance in Aspergillus fumigatus by Pyrosequencing
por: van der Torre, Mireille H., et al.
Publicado: (2020)

202 Antifungal Stewardship: The Clinician's Perspective on Barriers to Implementation
por: Safdar, Amar, et al.
Publicado: (2014)

Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis: Design, Development and Place in Therapy
por: Phillips, Nancy A, et al.
Publicado: (2023)

In Vitro Antifungal Activity of Ibrexafungerp (SCY-078) Against Contemporary Blood Isolates From Medically Relevant Species of Candida: A European Study
por: Quindós, Guillermo, et al.
Publicado: (2022)

Assessment of the In Vitro Antifungal Activity of SCY-078 Against a Collection of C. parapsilosis Clinical Isolates
por: Barat, Stephen, et al.
Publicado: (2017)

The Feasibility of Ibrexafungerp for the Treatment of Fungal Infections in Patients with Hematological Malignancies
por: Daraskevicius, Justinas, et al.
Publicado: (2022)

The challenges of the genome-based identification of antifungal resistance in the clinical routine
por: Alastruey-Izquierdo, Ana, et al.
Publicado: (2023)

A Novel Antifungal Is Active against Candida albicans Biofilms and Inhibits Mutagenic Acetaldehyde Production In Vitro
por: Nieminen, Mikko T., et al.
Publicado: (2014)

Exposure to Aspergillus in Home and Healthcare Facilities’ Water Environments: Focus on Biofilms
por: Richardson, Malcolm, et al.
Publicado: (2019)

Biotic Environments Supporting the Persistence of Clinically Relevant Mucormycetes
por: Richardson, Malcolm D., et al.
Publicado: (2019)

Clinical characteristics and outcomes in 303 HIV-infected patients with invasive fungal infections: data from the Prospective Antifungal Therapy Alliance registry, a multicenter, observational study
por: Marukutira, Tafireyi, et al.
Publicado: (2014)

Absence of Azole Antifungal Resistance in Aspergillus fumigatus Isolated from Root Vegetables Harvested from UK Arable and Horticultural Soils
por: van der Torre, Mireille H., et al.
Publicado: (2020)

EUCAST Ibrexafungerp MICs and Wild-Type Upper Limits for Contemporary Danish Yeast Isolates
por: Jørgensen, Karin M., et al.
Publicado: (2022)

Periodontal Disease and Late-Onset Aortic Prosthetic Vascular Graft Infection
por: Thomas, Stephanie, et al.
Publicado: (2015)

High-volume Sputum Culture for the Diagnosis of Pulmonary Aspergillosis
por: Vergidis, Pascalis, et al.
Publicado: (2017)

Epidemiology and Outcomes of Invasive Candidiasis Due to Non-albicans Species of Candida in 2,496 Patients: Data from the Prospective Antifungal Therapy (PATH) Registry 2004–2008
por: Pfaller, Michael A., et al.
Publicado: (2014)

The battle against fungi: lessons in antifungal stewardship from COVID 19 times()
por: Kanj, Souha S., et al.
Publicado: (2023)

Mold-Active Antifungal Prophylaxis in Pediatric Patients with Cancer or Undergoing Hematopoietic Cell Transplantation
por: Lehrnbecher, Thomas, et al.
Publicado: (2023)

2104. Susceptibility Trends in Antifungal Resistance (STAR) Study: Preliminary Data from A New Prospective Antifungal Surveillance Study
por: Ghannoum, Mahmoud, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6tbn3d7g8g3p39qq68pirt30q0